|
2025 Journal Article Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for ConcernSuo, Paulina, Srinivasan, Ashish, Thin, Lena, An, Yoon‐Kyo, Fernandes, Richard G., Ghaly, Simon, Jeffrey, Angus W., Menon, Shankar, Olsen, Nicholas, Skinner, Thomas, van Langenberg, Daniel R., Winston, James and Haifer, Craig (2025). Comparing Long‐Term Infliximab Persistence Following a Switch to a Biosimilar in Patients With Inflammatory Bowel Disease: No Cause for Concern. Journal of Gastroenterology and Hepatology. doi: 10.1111/jgh.16916 |
|
2025 Journal Article DOP015 Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s ProgramSu, W K, McNamara, J, Wilson, W, Wark, G, Lynch, K, Su, H, Forbes, A, Lawrance, I, An, Y K, Dutt, S, Brett, L, Walker, G, Andrews, J M, Connor, S J and Ghaly, S (2025). DOP015 Consistency and Quality of Inflammatory Bowel Disease care in Australasia; Towards Benchmarking, Crohn’s Colitis Cure Data Insight’s Program. Journal of Crohn's and Colitis, 19 (Supplement_1), i111-i112. doi: 10.1093/ecco-jcc/jjae190.0054 |
|
2025 Conference Publication Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessmentFernandes, R., Swe, E., Khaing, M. M., Gilmore, R., Khoo, E., An, Y. K. and Begun, J. (2025). Handheld ultrasound devices are an accurate alternative to cart-based ultrasound for IBD disease activity assessment. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.1349 |
|
2025 Journal Article P0603 The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn’s Colitis Cure Data Insight’s ProgramSu, W K, Wilson, W, Wark, G, Ghaly, S, Lynch, K, Lawrance, I, Walker, G, Forbes, A, Brett, L, An, Y K, Connor, S J and Andrews, J M (2025). P0603 The real-world use of intravenous and subcutaneous Vedolizumab in IBD across Australia and New Zealand, Crohn’s Colitis Cure Data Insight’s Program. Journal of Crohn's and Colitis, 19 (Supplement_1), i1197-i1198. doi: 10.1093/ecco-jcc/jjae190.0777 |
|
2025 Journal Article P0257 Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trialPudipeddi, A, Dhanji, P, Paramsothy, S, Kariyawasam, V, Paramsothy, R, Ghaly, S, Haifer, C, An, Y K, Begun, J, Connor, S, Corte, C, Ward, M, De Cruz, P, Fung, C, Redmond, D, Chan, W, Mourad, F, Kermeen, M and Leong, R (2025). P0257 Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial. Journal of Crohn's and Colitis, 19 (Supplement_1), i688-i689. doi: 10.1093/ecco-jcc/jjae190.0431 |
|
2024 Journal Article Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort studyGilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2024). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research. doi: 10.5217/ir.2024.00127 |
|
2024 Conference Publication Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated AnemiaBisht, Kavita, An, Yoon-Kyo, Shatunova, Svetlana, Wang, Ran, Barbier, Valerie, Giri, Rabina, Amiss, Anna, Tang, Yifu, Alexander, Kylie, Millard, Susan, Winkler, Ingrid G., Pettit, Allison, Begun, Jakob and Levesque, Jean-Pierre (2024). Endotoxemia As Possible Cause of Inflammatory Bowel Diseases-Associated Anemia. 66th ASH Annual Meeting, San Diego, CA United States, 7-10 December 2024. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2024-193349 |
|
2024 Journal Article Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease CoalitionAkyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2024). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089 |
|
2024 Journal Article Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trialPudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline Lan-San, Redmond, Diane, Chan, Webber, Mourad, Fadi, Kermeen, Melissa and Leong, Rupert W. (2024). Effects of thiopurine withdrawal on vedolizumab-treated patients with ulcerative colitis: a randomized controlled trial. Clinical Gastroenterology and Hepatology, 22 (11), 2299-2308. doi: 10.1016/j.cgh.2024.04.019 |
|
2024 Conference Publication Documented variation in inflammatory bowel disease care in Australasia : Crohn's Colitis Cure (CCC) data insights programSu, Wai Kin, Mcnamara, Jack, Pipicella, Joseph, Wilson, William, Ghaly, Simon, Cabaero, Aura Gesha, Walker, Gareth, Forbes, Angela, Su, Heidi, Brett, Laurel, Dutt, Shoma, An, Yoon-Kyo, Lawrance, Ian, Lynch, Kate, Andrews, Jane and Connor, Susan J. (2024). Documented variation in inflammatory bowel disease care in Australasia : Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case seriesSwe, Ei Phyu Phyu, Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2024). Efficacy of combination vedolizumab and upadacitinib treatment in refractory inflammatory bowel disease: a case series. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Exploring a novel score to assess the patient perceived burden of disease in Crohn's disease and ulcerative colitis: Crohn's Colitis Cure (CCC) data insights programSu, Wai Kin, Gu, Bonita, Pipicella, Joseph, Wilson, William, Kim, Andrew, Wark, Gabrielle, Giles, Edward, Walker, Gareth, Forbes, Angela, Su, Heidi, Dutt, Shoma, An, Yoon-Kyo, Lawrance, Ian, Lynch, Kate, Connor, Susan J. and Andrews, Jane (2024). Exploring a novel score to assess the patient perceived burden of disease in Crohn's disease and ulcerative colitis: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Dose escalated therapy improving outcomes in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights programSu, Wai Kin, Wilson, William, Ng, Watson, Whittaker, Clair, Giles, Edward, Walker, Gareth, Forbes, Angela, Lawrance, Ian, Dutt, Shoma, Lynch, Kate, Brett, Laurel, An, Yoon-Kyo, Connor, Susan J. and Andrews, Jane (2024). Dose escalated therapy improving outcomes in inflammatory bowel disease: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication The real-world use of five aminosalicylate treatment for ulcerative colitis: Crohn's Colitis Cure (CCC) data insights programSu, Wai Kin, Wilson, William, Pipicella, Joseph, Haifer, Craig, Williams, Astrid-Jane, Lynch, Kate, Forbes, Angela, Walker, Gareth, Schultz, Michael, Lawrance, Ian, An, Yoon-Kyo, Brett, Laurel, Connor, Susan J. and Andrews, Jane (2024). The real-world use of five aminosalicylate treatment for ulcerative colitis: Crohn's Colitis Cure (CCC) data insights program. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Journal Article Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central readingGoodsall, Thomas M., An, Yoon-Kyo, Andrews, Jane M., Begun, Jakob, Friedman, Antony B., Lee, Andrew, Lewindon, Peter J., Spizzo, Paul, Rodgers, Nick, Taylor, Kirstin M., White, Lauren S., Wilkens, Rune, Wright, Emily K., Zou, Lily, Maguire, Bryan R., Parker, Claire E., Rémillard, Julie, Novak, Kerri L., Panaccione, Remo, Feagan, Brian G., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2024). Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central reading. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2024.08.007 |
|
2024 Journal Article Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trialLittle, Robert D., McKenzie, Jo, Srinivasan, Ashish, Hilley, Patrick, Gilmore, Robert B., Chee, Desmond, Sandhu, Manjeet, Saitta, Daniel, Chow, Elizabeth, Thin, Lena, Walker, Gareth J., Moore, Gregory T., Lynch, Kate, Andrews, Jane, An, Yoon K., Bryant, Robert V., Connor, Susan J., Garg, Mayur, Wright, Emily K., Hold, Georgina, Segal, Jonathan P., Boussioutas, Alex, De Cruz, Peter, Ward, Mark G. and Sparrow, Miles P. (2024). Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial. BMJ Open, 14 (7) e081787, 1-8. doi: 10.1136/bmjopen-2023-081787 |
|
2024 Journal Article High technical success rate of endoscopic balloon dilatation reduces surgical requirement for patients with stricturing Crohn’s diseaseLim, Emily, Thai, Maxter, An, Yoon-Kyo, Hendy, Peter, Alchlaihawi, Mahmoud, Leong, Rupert, Connor, Susan, Ng, Watson, Gu, Bonita, Thin, Lena, Sparrow, Miles, Gilmore, Robert, Taylor, Kirstin, Sallis, Olivia, Andrews, Jane M., Daker, Charlotte, Gearry, Richard B., Wark, Gabrielle, Ghaly, Simon, Begun, Matt, Krishnaprasad, Krupa, Wu, Tianhong, Ruddick-Collins, Leonie, Schreiber, Veronika, Okano, Satomi, Radford-Smith, Graham, Schulberg, Julien, van Langenberg, Daniel and Begun, Jakob (2024). High technical success rate of endoscopic balloon dilatation reduces surgical requirement for patients with stricturing Crohn’s disease. GastroHep, 2024 (1) 3686618, 1-10. doi: 10.1155/2024/3686618 |
|
2024 Conference Publication Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisKhoo, Emi, Amiss, Anna, Ding, Nik S., Bryant, Robert V., Mohsen, Waled, Connor, Susan J., Leong, Rupert, Croft, Anthony, Lynch, Kate D., Sparrow, Miles, De Cruz, Peter, An, Yoon-Kyo, Holtmann, Gerald J. and Begun, Jakob (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Digestive Disease Week (DDW) 2024, Washington, DC, United States, 18-21 May 2024. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(24)00988-0 |
|
2024 Conference Publication A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient SatisfactionFernandes, Richard G., Khoo, Emi, Harris, Heidi Jensen, Gilmore, Robert, Khaing, Myat Myat, Begun, Jakob and An, Yoon-Kyo (2024). A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)01652-4 |
|
2024 Other Outputs Australia Ustekinumab Real-world Observational Research (AURORA)An, Yoon-Kyo (2024). Australia Ustekinumab Real-world Observational Research (AURORA). PhD Thesis, Faculty of Medicine, The University of Queensland. doi: 10.14264/292cc48 |
